Reprogramming the immune system using antibodies.

Reprogramming the immune system using antibodies.

Tolerance induction induced by monoclonal antibodies or co-receptor blockade is robust enough to resist breakdown by adoptive transfer of lymphocytes. Such resistance, the hallmark of dominant tolerance, is mediated by CD4+ regulatory T cells. CD4+CD25+ T cells inhibit lymphopenia-mediated accumulat...

Descripció completa

Dades bibliogràfiques
Autors principals:	Graca, L, Waldmann, H
Format:	Journal article
Idioma:	English
Publicat:	2006

Ítems similars

Reprogramming the immune system for tolerance with monoclonal antibodies.
per: Cobbold, S, et al.
Publicat: (1990)

Reprogramming the immune system.
per: Waldmann, H
Publicat: (2008)

Reprogramming the immune system.
per: Waldmann, H
Publicat: (2002)

REPROGRAMMING THE IMMUNE-SYSTEM
per: Waldmann, H, et al.
Publicat: (1993)

Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies.
per: Cobbold, S, et al.
Publicat: (1992)

Prospects for reprogramming the immune system in multiple sclerosis
per: Waldmann, H
Publicat: (2007)

Reprogramming the immune system towards regulation
per: Waldmann, H, et al.
Publicat: (2010)

Reprogramming the immune system: co-receptor blockade as a paradigm for harnessing tolerance mechanisms.
per: Waldmann, H, et al.
Publicat: (2008)

Reprogramming the immune system: a possible therapeutic approach to established autoimmune disease.
per: Waldmann, H, et al.
Publicat: (1993)

INTERACTION OF MONOCLONAL-ANTIBODIES WITH THE IMMUNE-SYSTEM
per: Clark, M, et al.
Publicat: (1986)

Antibody-induced transplantation tolerance: the role of dominant regulation.
per: Graca, L, et al.
Publicat: (2003)

Similarities in the Metabolic Reprogramming of Immune System and Endothelium
per: Chu-Yik Tang, et al.
Publicat: (2017-07-01)

GPC2 antibody–drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies
per: Paul M Sondel, et al.
Publicat: (2022-12-01)

Human monoclonal antibodies: the residual challenge of antibody immunogenicity.
per: Waldmann, H
Publicat: (2014)

Cutting edge: anti-CD154 therapeutic antibodies induce infectious transplantation tolerance.
per: Graca, L, et al.
Publicat: (2000)

The use of monoclonal antibodies to achieve immunological tolerance.
per: Waldmann, H, et al.
Publicat: (1993)

The use of monoclonal antibodies to achieve immunological tolerance.
per: Waldmann, H, et al.
Publicat: (1993)

Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk
per: Kyle K. Payne, et al.
Publicat: (2012-01-01)

Understanding and Modulating Immunity With Cell Reprogramming
per: Cristiana F. Pires, et al.
Publicat: (2019-12-01)

The cancer metabolic reprogramming and immune response
per: Longzheng Xia, et al.
Publicat: (2021-02-01)

MONOCLONAL-ANTIBODY THERAPY IN SYSTEMIC VASCULITIS
per: Mathieson, P, et al.
Publicat: (1990)

Mitochondrial metabolic reprogramming of macrophages and T cells enhances CD47 antibody-engineered oncolytic virus antitumor immunity
per: Ping Cheng, et al.
Publicat: (2024-12-01)

Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies.
per: O'Neill, J, et al.
Publicat: (1993)

Lipid Metabolism Reprogramming of Immune Cells in Acne: An Update
per: Wu S, et al.
Publicat: (2023-09-01)

Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma
per: Songlei Zhou, et al.
Publicat: (2023-01-01)

Prospects for the application of antibodies in medicine.
per: Waldmann, H
Publicat: (2000)

SIRPα antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment
per: Defeng Kong, et al.
Publicat: (2022-10-01)

Regulation of Immune Cell Functions by Metabolic Reprogramming
per: Jaehong Kim
Publicat: (2018-01-01)

Targeting macrophages to reprogram the tumor immune microenvironment
per: Zhidong Xie, et al.
Publicat: (2024-10-01)

Metabolic Reprogramming and Immune Evasion in Nasopharyngeal Carcinoma
per: Huimei Huang, et al.
Publicat: (2021-09-01)

Polylactide Degradation Activates Immune Cells by Metabolic Reprogramming
per: Chima V. Maduka, et al.
Publicat: (2023-11-01)

Impact of epigenetic reprogramming on antitumor immune responses in glioma
per: Brandon L. McClellan, et al.
Publicat: (2023-01-01)

Manipulation of T-cell responses with monoclonal antibodies.
per: Waldmann, H
Publicat: (1989)

The major histocompatibility system and the immune response.
per: Munro, A, et al.
Publicat: (1978)

Hybrid antibodies for therapy.
per: Clark, M, et al.
Publicat: (1988)

Limiting dilution analysis of the cells of immune system I. The clonal basis of the immune response.
per: Lefkovits, I, et al.
Publicat: (1984)

THERAPY WITH HYBRID ANTIBODIES
per: Clark, M, et al.
Publicat: (1989)

Monoclonal antibodies for organ transplantation: prospects for the future.
per: Waldmann, H
Publicat: (1988)

TOLERANCE INDUCTION USING CD4 AND CD8 MONOCLONAL-ANTIBODIES
per: Waldmann, H, et al.
Publicat: (1989)

Human placental exosomes induce maternal systemic immune tolerance by reprogramming circulating monocytes
per: Kunfeng Bai, et al.
Publicat: (2022-02-01)